SOURCE: Burrill & Company

Burrill & Company

November 04, 2011 09:15 ET

Biotech Visionary G. Steven Burrill Honored With Scrip Lifetime Achievement Award

Burrill & Company CEO Recognized for Contributions Made During More Than 40 Years of Work in the Life Sciences Industry

SAN FRANCISCO, CA--(Marketwire - Nov 4, 2011) - G. Steven Burrill, a biotech industry visionary and CEO of Burrill & Company, received a lifetime achievement award during Scrip Intelligence's annual Scrip Award ceremony held in London November 3.

Scrip Intelligence, a leading news, data, and information service for the global pharmaceutical industry, used an independent panel of 16 senior industry experts to select honorees for their contributions to the advancement of science and improvement of healthcare worldwide.

"It has been my good fortune to have worked for more than 40 years within the biotech industry and contribute to companies tackling the greatest challenges facing our world today, from the development of drugs to treat diseases without adequate therapies to addressing the need to develop new and affordable sources of renewable energy," says G. Steven Burrill. "I am honored to receive this recognition."

An early pioneer, Burrill is one of the original architects of the industry and one of its most avid and sustained developers.

He currently serves as a member of the boards of directors of Catalyst Biosciences, Depomed, NewBridge Pharmaceuticals, Proventys, Targacept, and Expression Diagnostics. He previously served as Chairman of the Boards of Abunda Nutrition, BioImagene and Pharmasset.

Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology, life sciences, high technology, and manufacturing industries worldwide.

In 2002, Scientific American magazine recognized Burrill as a biotech investment visionary naming him to The Scientific American 50. He has also been honored at the American Liver Foundation's Annual "Salute to Excellence" Gala, which honors the best and the brightest from the San Francisco Bay Area's medical, biotech, and bio-pharmaceutical industries. In 2008 he received the BayBio Pantheon 2008 DiNA lifetime achievement award for his worldwide biotech leadership.

In addition to his work with leading life science companies, Mr. Burrill is a founder and currently serves as chairman of the board of the National Science & Technology Medals Foundation. Additionally, he serves as chairman of the San Francisco Mayor's Biotech Advisory Committee. Burrill also chaired the National Research Council study on linkages in biotechnology between Japan and the United States.

He was also involved with the U.S.-Japan Science and Technology Agreement Study of Technology Transfer Mechanisms between the United States and Japan. Other not-for-profit activities include serving on the boards of directors of the Bay Area Science Infrastructure Consortium, BayBio (emeritus), California Healthcare Institute (emeritus), The Exploratorium (emeritus), The Kellogg Center for Biotechnology, the MIT Center for Biomedical Innovation, and the National Health Museum (vice chairman), World Council for Ethical Standards (chairman), Vilas County Economic Development Group (chairman), BIO Ventures for Global Health (BVGH), University of Wisconsin Extension, Scientific American Board of Advisors. He also serves on the editorial board of the Journal of Commercial Biotechnology and is on the advisory boards of the Center for Policy on Emerging Technologies, as well as BioAg Gateway, City of Madison.

He is an advisor to University of Illinois Institute for Genomic Biology, University of Wisconsin-College of Agriculture and Life Sciences, University of Minnesota College of Biological Sciences, and Duke University. He is also an adjunct professor at University of California, San Francisco.

About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than $1 billion in assets under management, the firm's businesses include venture capital, private equity, merchant banking, and media. By leveraging the scientific and business networks of its investment team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: www.burrillandco.com.

Contact Information

  • Contact:
    Daniel Levine
    Managing Director
    Burrill & Company
    Email Contact
    415-591-5449